LIPO
Income statement / Annual
Last year (2024), Lipella Pharmaceuticals Inc.'s total revenue was $536.36 K,
an increase of 19.29% from the previous year.
In 2024, Lipella Pharmaceuticals Inc.'s net income was -$5.02 M.
See Lipella Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$536.36 K |
$449.62 K |
$184.16 K |
$259.35 K |
$961.68 K |
$694.75 K |
| Cost of Revenue |
$3.61 M
|
$3.04 M
|
$2.55 M
|
$1.46 M
|
$975.96 K
|
$682.89 K
|
| Gross Profit |
-$3.08 M
|
-$2.59 M
|
-$2.36 M
|
-$1.20 M
|
-$14.28 K
|
$11.86 K
|
| Gross Profit Ratio |
-5.74
|
-5.76
|
-12.83
|
-4.62
|
-0.01
|
0.02
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$2.55 M
|
$1.46 M
|
$975.96 K
|
$682.89 K
|
| General & Administrative Expenses |
$2.00 M
|
$2.16 M
|
$226.19 K
|
$718.38 K
|
$42.59 K
|
$65.65 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.00 M
|
$2.16 M
|
$226.19 K
|
$718.38 K
|
$42.59 K
|
$65.65 K
|
| Other Expenses |
$0.00
|
$0.00
|
-$2.55 M
|
-$1.46 M
|
-$975.96 K
|
-$682.89 K
|
| Operating Expenses |
$2.00 M
|
$2.16 M
|
$226.19 K
|
$718.38 K
|
$42.59 K
|
$65.65 K
|
| Cost And Expenses |
$5.62 M
|
$5.20 M
|
$2.77 M
|
$2.18 M
|
$1.02 M
|
$748.54 K
|
| Interest Income |
$64.28 K
|
$137.84 K
|
$1.68 K
|
$104.00
|
$3.17 K
|
$334.00
|
| Interest Expense |
$0.00
|
$10.85 K
|
$9.61 K
|
$6.83 K
|
$7.97 K
|
$8.39 K
|
| Depreciation & Amortization |
$2.89 K
|
$1.69 K
|
$0.00
|
$0.00
|
$0.00
|
$53.79 K
|
| EBITDA |
-$5.01 M |
-$4.61 M |
-$2.59 M |
-$1.86 M |
-$53.69 K |
$0.00 |
| EBITDA Ratio |
-9.35
|
-10.25
|
-14.05
|
-7.17
|
-0.06
|
0
|
| Operating Income Ratio |
-9.47
|
-10.56
|
-14.06
|
-7.39
|
-0.06
|
-0.08
|
| Total Other Income/Expenses Net |
$64.28 K
|
$126.99 K
|
-$7.98 K
|
$50.36 K
|
-$4.79 K
|
-$8.06 K
|
| Income Before Tax |
-$5.02 M
|
-$4.62 M
|
-$2.60 M
|
-$1.87 M
|
-$61.66 K
|
-$61.85 K
|
| Income Before Tax Ratio |
-9.35
|
-10.27
|
-14.11
|
-7.19
|
-0.06
|
-0.09
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$5.02 M
|
-$4.62 M
|
-$2.60 M
|
-$1.87 M
|
-$61.66 K
|
-$61.85 K
|
| Net Income Ratio |
-9.35
|
-10.27
|
-14.11
|
-7.19
|
-0.06
|
-0.09
|
| EPS |
-4.79 |
-6.16 |
-5.12 |
-4 |
-0.23 |
-0.24 |
| EPS Diluted |
-4.79 |
-6.16 |
-5.12 |
-4.38 |
-0.23 |
-0.24 |
| Weighted Average Shares Out |
$1.05 M
|
$749.83 K
|
$507.36 K
|
$466.48 K
|
$266.40 K
|
$260.00 K
|
| Weighted Average Shares Out Diluted |
$1.05 M
|
$750.38 K
|
$507.58 K
|
$426.01 K
|
$266.40 K
|
$260.00 K
|
| Link |
|
|
|
|
|
|
